Details:
Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Adakveo (crizanlizumab) is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions between endothelial cells, platelets, RBCs, and leukocytes and indicated for sickle cell disease.
Lead Product(s): Crizanlizumab
Therapeutic Area: Hematology Product Name: Adakveo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2023
Details:
Adakveo (crizanlizumab) is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions between endothelial cells, platelets, RBCs, and leukocytes and indicated for sickle cell disease.
Lead Product(s): Crizanlizumab-tmca
Therapeutic Area: Hematology Product Name: Adakveo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition August 02, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition December 14, 2021
Details:
Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.
Lead Product(s): Human Fibrinogen
Therapeutic Area: Hematology Product Name: Fibryga
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
A pre-specified sensitivity analysis considering the impact of the COVID-19 pandemic, revealed a statistically significant difference in favor of Ferinject® on cardiovascular mortality and hospitalization for heart failure.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Ferinject
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020